Scholarlink

<p>Circulating tumor DNA (ctDNA) is a promising marker with a strong prognostic value in metastatic pancreatic ductal adenocarcinoma (mPDAC). However, ctDNA is not detected in about a third of patients with mPDAC. The objective of this study was to assess the correlation between ctDNA and tumor volume (TV). In this monocentric cohort of mPDAC patients naïve for chemotherapy, ctDNA quantity at baseline (before chemotherapy initiation) was assessed by droplet-based digital PCR targeting two methylated markers (HOXD8 and POU4F1). TV was measured in 3D, for the primary lesion and the metastatic sites, from baseline thoraco-abdomino-pelvic computed tomography (CT) scan. Among the 71 included patients, ctDNA was detected in 47 patients (66.2%). There was a significant correlation of total and liver TV with ctDNA quantity, with Spearman’s ρ of 0.353 (<i>p</i> = 0.01) and 0.500 (<i>p</i> &lt; 0.001), respectively. Total and liver TV were higher in patients with detected ctDNA (129.5 vs. 31.8&#xa0;mL, <i>p</i> = 0.002 and 18 vs. 1&#xa0;mL, <i>p</i> &lt; 0.001, respectively). Total and liver TV thresholds of 90.1 and 3.7&#xa0;mL were associated with ctDNA detection, respectively. In conclusion, this study demonstrates, in patients with mPDAC, a moderate correlation between ctDNA and TV in mPDAC, especially for liver metastases TV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月7日

查看全文
  • Olivier Caliez,
  • Mathilde Wagner,
  • Valérie Taly,
  • Léo Mas,
  • Solène Doat,
  • Daniel Pietrasz,
  • Pierre Laurent-Puig,
  • Jean-Baptiste Bachet

摘要

Circulating tumor DNA (ctDNA) is a promising marker with a strong prognostic value in metastatic pancreatic ductal adenocarcinoma (mPDAC). However, ctDNA is not detected in about a third of patients with mPDAC. The objective of this study was to assess the correlation between ctDNA and tumor volume (TV). In this monocentric cohort of mPDAC patients naïve for chemotherapy, ctDNA quantity at baseline (before chemotherapy initiation) was assessed by droplet-based digital PCR targeting two methylated markers (HOXD8 and POU4F1). TV was measured in 3D, for the primary lesion and the metastatic sites, from baseline thoraco-abdomino-pelvic computed tomography (CT) scan. Among the 71 included patients, ctDNA was detected in 47 patients (66.2%). There was a significant correlation of total and liver TV with ctDNA quantity, with Spearman’s ρ of 0.353 (p = 0.01) and 0.500 (p < 0.001), respectively. Total and liver TV were higher in patients with detected ctDNA (129.5 vs. 31.8 mL, p = 0.002 and 18 vs. 1 mL, p < 0.001, respectively). Total and liver TV thresholds of 90.1 and 3.7 mL were associated with ctDNA detection, respectively. In conclusion, this study demonstrates, in patients with mPDAC, a moderate correlation between ctDNA and TV in mPDAC, especially for liver metastases TV.